Skip to content

Clinical trials

Observational Asthma trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Asthma Phase: Observational Country / region: China Clear all

60 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20071
20081
20091
20111
20121
20132
20143
20154
20164
20171
20184
20191
20202
20214
20225
20235
20249
20256
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed22
Recruiting16
Unknown status15
Not yet recruiting4
Active, not recruiting1
Suspended1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca7
Guangzhou Institute of Respiratory Disease5
Second Affiliated Hospital, Zhejiang University, School of Medicine5
Peking University Third Hospital4
Beijing Chao Yang Hospital2
China Academy of Chinese Medical Sciences2
First Affiliated Hospital of Ningbo University2
Henan University of Traditional Chinese Medicine2
Shanghai Children's Medical Center2
Shanghai Jiao Tong University School of Medicine2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Asthma60
Pulmonary Disease, Chronic Obstructive12
Rhinitis, Allergic7
Bronchiectasis5
Dermatitis, Atopic3
Disease3
Hypersensitivity3
Aspergillosis, Allergic Bronchopulmonary2
Bronchitis2
Emphysema2

Trials

Showing 1 to 25 of 60. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.